New pooled data from the Phase III FIBRONEER trials were recently presented at the European Respiratory Society Congress. Nerandomilast is an oral medicine...
United Therapeutics now has fresh late stage data on Tyvaso sitting in a top tier journal, which represents a clear milestone for any drug developer. With the...
The p300/CBP inhibitors suppressed fibrotic phenotypes in both in vitro human and in vivo mouse models of pulmonary fibrosis, demonstrating the effectiveness of...
Expanded Therapeutic Potential: These findings position Thykamine as a promising disease-modifying candidate for pulmonary fibrosis and other fibro-inflammatory...
The researchers' analyses zeroed in on two TGF-beta-related genes, ACVRL1 and LTBP1, that appear to play central roles in IPF lung disease. Specifically, data...
A study that evaluated people with IPF waiting for lung transplants found higher death rates among Black and Hispanic patients.
After the approval of JASCAYD® in the U.S. to treat patients with idiopathic pulmonary fibrosis (IPF), Boehringer Ingelheim is pursuing new research...
With a second phase 3 win for Tyvaso in idiopathic pulmonary fibrosis (IPF), United Therapeutics is padding the case for an expansion.
AK3280 is an optimized, small-molecule, broad-spectrum anti-fibrotic agent. In a Phase 2 proof-of-concept study conducted in China, AK3280 demonstrated...
In summary, single-cell profiling of diagnostic-stage IPF ALI cultures revealed epithelial and mesenchymal programmes defined by profibrotic basal cells, primed...
Newest 20 creators from Luxembourg
No members match your search.
